Changes in blood levels of surfactant protein-A (SP-A) — immune proteins most abundant in the lungs — can help predict treatment outcomes with anti-fibrotic therapies, including Esbriet and Ofev, in people with idiopathic pulmonary fibrosis (IPF), a study found. According to the new study, serial measurements…
The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.
Most of the conversations in the Pulmonary Fibrosis News Forums are about the physical and medical aspects of living with idiopathic pulmonary fibrosis (IPF). But occasionally we steer off-topic and talk about who we are as people first and patients second. We talk about our families, travel plans,…
Prolidase deficiency, an inherited enzymatic disease, may cause combined pulmonary fibrosis and emphysema (CPFE) syndrome in adulthood, a case study suggests. The report, “Prolidase deficiency: a new genetic cause of combined pulmonary fibrosis and emphysema syndrome in the adult,” was published in the European…
A high number of bacteria in the lungs of people with idiopathic pulmonary fibrosis (IPF) is linked to disease progression and to an increased risk of mortality, a study found. The study, “Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and…
A roadblock to your future could be any number of things. Perhaps it is a new skill necessary to advance your career or the finances needed for a big purchase. Those are normal hurdles that many have to overcome to achieve their goals. A life-threatening lung disease is an abnormal…
A new technique to create lung cells from other, more easily accessible cell types could be useful for understanding diseases like idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). The technique was described in an article, “Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity…
The European Patent Office (EPO) has issued a “notice of intent” to grant a patent to MN-001 (tipelukast), MediciNova’s investigational oral therapy for idiopathic pulmonary fibrosis (IPF). Once issued, the patent will…
As I sit down to write this column, I am having a difficult day. Following a recent column about vulnerability, I heard from many readers who said my words encouraged them to express their own vulnerabilities. As a result of that feedback, I want to share that today I…
People with idiopathic pulmonary fibrosis have shorter telomeres — the protective caps at the end of chromosomes — but shortening may occur prior to disease onset. The study with that finding, “From organ to cell: Multi-level telomere length assessment in patients with idiopathic pulmonary fibrosis,” was published…
Get regular updates to your inbox.
